VIKING THERAPEUTICS INC

NASDAQ: VKTX (Viking Therapeutics, Inc.)

Last update: yesterday, 8:31PM

29.22

1.64 (5.95%)

Previous Close 27.58
Volume 8,870,639
Price / Book 6.33
52 Weeks Range
23.82 (-18%) — 43.10 (47%)
Diluted EPS (TTM) -1.54
Total Debt/Equity (MRQ) 0.11%
Current Ratio (MRQ) 25.86
Operating Cash Flow (TTM) -152.54 M
Levered Free Cash Flow (TTM) -102.10 M
Return on Assets (TTM) -14.99%
Return on Equity (TTM) -19.99%

AIStockmoo Score

0.0
Value 30% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 30% -1.8
From our AI technical analysis of the chart. info NA
Downtrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.3
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
Smart Money 20% 2.7
Insider Activity info NA
Institutions net +3.61% of shares in their latest 13F filings: 244 holders increased, 194 decreased (quarter to 30 Sep 2026). info
Short interest +8.9% from 31 Aug to 30 Oct 2026, 5.4 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Not in score
Price is low against its 52-week average. Up over 5 years. info
Short-term momentum rising. info
Price is near resistance. info
Final Score 0.04

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Viking Therapeutics, Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
VKTX - - - 6.33
VRNA 9 B - - 33.01
OPT 583 M - - 4.31
VRCA - - - 15.60
TSHA - - - 3.74
ABEO - - - 1.04

Select this tab to load the latest available analysis.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 2.15%
% Held by Institutions 70.06%

No data within this time range.

Institutions

Institutional ownership: 72.13%

Positions Holders Shares
Increased 244 12,854,831
Decreased 194 7,705,000
New 74 2,130,763
Sold out 67 2,661,975

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 24,163,022 5.4
15 Oct 2026 25,538,849 4.4
30 Sep 2026 25,921,759 2.2
15 Sep 2026 22,583,758 12.3
31 Aug 2026 22,186,520 12.4
14 Aug 2026 22,285,459 13.3

FINRA short interest via Nasdaq, reported twice a month.

3 Positive 1 Negative 5 Neutral
Date Type Details
13 Nov 2026 Yahoo Finance 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
13 Nov 2026 Yahoo Finance Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
12 Nov 2026 Yahoo Finance Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
Viking Therapeutics (VKTX) is heading into a busy stretch on the conference circuit, with back to back presentations at the Stifel 2026 Healthcare Conference and the Truist Securities BioPharma Symposium in New York next week. Recent trading tells a mixed story for Viking Therapeutics. The share…
11 Nov 2026 Yahoo Finance Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
Viking Therapeutics has delivered very strong long term share returns, and that kind of history can leave investors wondering whether the current US$28.44 price still lines up with what its balance sheet says the business is worth. With the spotlight on Viking Therapeutics as it pushes ahead in…
11 Nov 2026 Yahoo Finance Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
These drugmakers offer very different risk-reward profiles.
09 Nov 2026 Yahoo Finance Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will present two posters highlighting its VK2735 program at The Obesity Society's Annual…
04 Nov 2026 Yahoo Finance Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking aims to enter the weight loss drug market.
03 Nov 2026 Yahoo Finance Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium…
02 Nov 2026 Yahoo Finance UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.
30 Oct 2026 Yahoo Finance VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.
30 Oct 2026 Yahoo Finance Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
29 Oct 2026 Yahoo Finance VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
29 Oct 2026 Yahoo Finance LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised
Lilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
29 Oct 2026 Yahoo Finance Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly just posted a quarter that left its GLP-1 rivals in the dust, but margin pressure and a $900 million pile of one-time benefits raise questions about how much of that strength is real and how long it can last.
Show more

Recent Signals candle patterns and EMA crosses

▲ Bullish EMA cross 4 sessions ago · 09 Nov
Short term · EMA 7/20
The 7-day EMA crossed above the 20-day: short-term momentum turned up.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria